Q-omics provides the consensus-scored FBXO40 profile across patient tissues and cancer cell-line models. FBXO40 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FBXO40 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, FBXO40 RNA expression shows 15,598 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, COAD, and GBM as cancer lineages where FBXO40 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO40 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO40 survival associations across molecular data types. FBXO40 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO40 RNA expression–survival associations across cancer types. High FBXO40 expression shows unfavorable associations in MESO, OV, COAD, READ and LUSC, but favorable associations in BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FBXO40 RNA expression.
This table summarizes FBXO40 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FBXO40. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO40 shows lower tumor expression in COAD, HNSC, KIRP, KIRC, LUSC and UCEC. The COAD box plot shows higher FBXO40 RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p < 0.001).
This table shows molecular features associated with FBXO40 in patient tissues and cancer cell lines. In patient samples, FBXO40 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO40 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
